Lean on me? That’s unless you DIE from an adverse reaction of course!!!

Posted by Claire O’Keeffe,

Sunday, October 17, 2010 Excerpt:

Anti-depressants manufacturer funds depression-awareness campaign

Lundbeck, a pharmaceuticals giant and a major manufacturer of antidepressants, has fully funded an Irish depression awareness campaign called Lean on Me.

The Lundbeck-sponsored campaign, which was launched by singers, Johnny Logan and Niamh Kavanagh on 1st October, encourages people to support loved ones who are experiencing depression, as well as encouraging a better understanding of the condition.

Lundbeck’s primary product is Cipramil, the world’s most-prescribed new-generation antidepressant. Cipramil alone accounts for some 82 per cent of the company’s sales.

This pharmaceuticals company has given an unrestricted educational grant to the Lean on Me campaign and it claims mental health organisation, Aware and The European Depression Association (EDA) as its supporters.

“Paul David Klemperer is an economist and professor of Economics at Oxford University. He said: “When groups accept financial support from the pharmaceutical industry and medical device manufacturers this constitutes an increasingly important marketing component for the [pharmaceuticals company].”

A member of the pharmaceuticals industry who wishes to remain unnamed says,
“Once you scratch the surface you would be amazed how many organisations without the necessary resources avail of external resources like pharmaceutical companies. You then feel like you must align yourself with what those companies want. Questions should be asked about this.”

Lundbeck Ireland declined to comment on their funding of the Lean on Me campaign.

Posted by Claire O’Keeffe

 

Conflict of interest??

Is Ireland being bought by pharmaceutical companies?

1. Drug trials done on children in Irish childrens homes.

2. Lundbeck and Irish psychiatry denying links to suicide/homicide with ssri’s.

3. Off label prescribing of ssri’s for Irish children  (under 16′s  and including the notorious seroxat) 

4. Elan the €3bn-valued Athlone-headquartered company  agreed to pay the biggest fine in Irish corporate history, when it coughed up almost €147m as part of an agreement to resolve US criminal and civil investigations into the illegal marketing of an epilepsy drug.

5. Psychiatry Ireland ignores Irish ssri expert Professor David Healy because he dared to speak out about the  possible adverse side effects of these drugs.

6. The persecution of the late Dr. Michael Corry for daring to speak out about the side effects of ssri’s inc suicide/homicide.

Lundbeck – campaign sponsor

Lundbeck is an international pharmaceutical company that is deeply committed to improving quality of life (unless you die from their drug of course)  for persons who have a disease of the central nervous system (CNS), like depression. Lundbeck sponsors the ‘Lean on Me’ campaign with an unrestricted educational grant.

LET’S NOT FORGET THE E.U. RECOMMENDATIONS..(Which psychiatry Ireland will deny)

August 19, 2005

European Union

Drug Class: Newer Antidepressants

Drug Name: Fluoxetine, Fluvoxamine, Sertraline, Paroxetine, Citalopram, Escitalopram, Atomoxetine, Duloxetine, Venlafaxine, Mianserin, Milnacipram, Reboxetine, Mirtazapine

Age: Children (under 18)

Side Effects: Suicide Risk/Suicide Attempts/Suicide, Aggression, Violence, Hostility

Summary: The Commission of the European Communities, representing 25 European countries, endorsed and issued the strongest warning yet against child antidepressant use as recommended by Europe’s Committee for Medicinal Products for Human Use (CHMP). Clinical trials had shown that the drugs caused suicidal behavior including suicide attempts and suicidal ideation, aggression, hostility (predominantly aggression, oppositional behavior and anger) and/or related behavior.

 

Source: Commission of the European Communities Commission Decision concerning the placement on the market, under Article 21 of the Directive 2001/83/EC of the European Parliament and of the Council, Brussels 19-VIII-2005, C (2205) 3256.

 

 

Germany Drug Warning, March 10, 2009

Drug Class: Older Antidepressants, Newer Antidepressants including CITALOPRAM.

Age: Adults (18 and over)

Side Effects: Suicide Risk/Suicide Attempts/Suicide

Summary: The German Drug Regulatory Agency (BfArM) issued an official notice to the pharmaceutical companies that the approval for all newer antidepressants on the market has been changed. BfArM now requires the package information leaflets for newer antidepressants to include information on the increased risk of suicidal behavior in adults under 25 years.

 

 

Pharmacovigilance Working Party  

A meta-analysis of placebo-controlled clinical trials of antidepressant drugs in adult patients with psychiatric disorders showed an increased risk of suicidal behaviour with antidepressants compared to placebo in patients less than 25 years old.

If you are a young adult. Information from clinical trials has shown an increased risk of suicidal behaviour in adults aged less than 25 years with psychiatric conditions who were treated with an antidepressant.

 

 

Based on this review the FDA’s Psychopharmacologic Drugs Advisory Committee agreed that labelling changes were required to inform health care professionals about the potential for an increased risk of suicidality in younger adults (aged 18 to 24) using antidepressants during the initial phases of treatment (generally the first one to two months).  

 

 

 

 

 

 

 

Based on this review the FDA’s Psychopharmacologic Drugs Advisory Committee agreed that labelling changes were required to inform health care professionals about the potential for an increased risk of suicidality in younger adults (aged 18 to 24) using antidepressants during the initial phases of treatment (generally the first one to two months).  

January 2008

For bupropion, citalopram, escitalopram and fluvoxamine there is a trend towards an increased risk of suicidal behaviour with that for citalopram being most marked but does not reach statistical significance for any of these drugs. ( Only DOUBLE that of  placebo?)